IBDoc® IBDoc® is the first self-testing application for fecal calprotectin in IBD patients that involves three easy steps. Based on BÜHLMANN’s long-lasting experience with calprotectin assays, IBDoc® provides IBD patients a convenient method for self-testing. CALEX® Valve has been developed for simple and easy-to-handle stool extraction with a valve designed to allow the precise application
Continue Reading
Category: IBDoc® News
US: IBDoc® is NOT available for sale in the US.
Canada: Health Canada License: 98903, Device class: 3
Meeting of the Minds 2019 BUHLMANN Diagnostics Corp Stop by our Booth! Nov 15-16, 2019 | Ritz Carlton Hotel | Toronto, ON Event Info: https://crohnsandcolitis.ca/meetingoftheminds Visit our booth to get an update on our IBDoc® Calprotectin Home Test: IBDoc®, the in-vitro diagnostic POC and home testing device to measure the inflammatory marker, fecal calprotectin Learn More Click & Contact Meeting of the Minds
Continue Reading
New IBDoc® Tutorials (available on: ibdoc.net) IBDoc® Portal Tutorial videos offer: Quick and easy training for the sites to learn the important portal functionalities Updated healthcare professional and patient training Who Are the Videos for? Clinical Administrators Clinical Users View these six new IBDoc® Portal Tutorial Videos. They are geared toward helping Healthcare Professionals that
Continue Reading
Benefits for Patients and Healthcare Staff of Routine IBDoc® Use Kathleen Sugrue, Advanced Nurse Practitioner at Mercy University Hospital, Cork (Article courtesy of BÜHLMANN’s UK distributor, Alpha Laboratories.) Highlight from this Perspective Article “Since introducing IBDoc® we get less calls on the helpline because patients can check themselves if they are concerned they are flaring.” “Patients
Continue Reading
Read a recent article written from the perspective of a long term Crohn's sufferer who shares his experience of managing the disease with the help of calprotectin self-testing. Article courtesy of BÜHLMANN’s UK distributor, Alpha Laboratories. Highlight from this Perspective Article “It has reduced the “waiting time” for results down to hours instead of days or
Continue Reading
Read a recent article from University of Otago on the success of a new smartphone app, IBDSmart, in synergy with BÜHLMANN IBDoc calprotectin home test. Highlight from this Article "The study showed there was no difference in terms of quality of life for patients whether they used the apps or had face-to-face meetings,” Associate Professor
Continue Reading
Health Canada Licence: 98903, Device class: 3 BÜHLMANN IBDoc® is not available for sale in the US. IBDoc® is the first self-testing application for fecal calprotectin in IBD patients that involves three easy steps. IBDoc® allows IBD patients convenient self-testing of fecal calprotectin. Teleconference Overview Goal of Discussion The goal was for Clinical Administrators and Clinical Users from
Continue Reading
US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Read a recent article in the Journal of mHealth (Volume 3, Issue 3), McCombie and colleagues performed a systematic review of IBD symptom monitoring smartphone apps. Highlight from this Article In this study, 233 separate apps were found on
Continue Reading
US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Read a recent interview with Lead Inflammatory Bowel Disease Nurse, Pearl Avery, conducted by BÜHLMANN's UK distributor Alpha Laboratories: Highlight from this Article “In the six months that we have been working with the IBDoc, one patient was
Continue Reading
US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 BÜHLMANN was nominated to receive the Swiss Medtech Award for 2018 for the IBDoc® calprotectin smartphone-based rapid test About Swiss MEDTECH Swiss Medtech was established on 12 June 2017 following the merger of two national medtech organizations, FASMED and Medical Cluster.
Continue Reading
